gunnar

As one of the leading global events in cell and gene therapy, ISCT brings together experts, innovators, and industry leaders to shape the future of advanced therapies.

You’ll find us at our booth, where we’ll be showcasing our latest solutions and connecting with partners across the field. We look forward to insightful discussions and new collaborations in Dublin.

This key event brings together scientists and industry professionals focused on the latest advances in cell-based technologies and drug discovery.

Visit us at our booth to discover our latest innovations and meet the team. We’re looking forward to engaging conversations and new opportunities in Göteborg.

This key event brings together scientists and industry professionals focused on the latest advances in cell-based technologies and drug discovery.

Visit us at our booth to discover our latest innovations and meet the team. We’re looking forward to engaging conversations and new opportunities in Vienna.

Hosted by ELRIG, a not‑for‑profit organisation dedicated to advancing the global drug discovery community through open‑access scientific events, this free‑to‑attend conference brings together leading scientists, innovators and industry professionals to explore the latest breakthroughs and emerging technologies shaping the future of drug discovery.

The event offers high‑quality scientific sessions, networking opportunities and an engaging exhibition — a unique platform to connect, collaborate and stay at the forefront of life science research.

This premier global gathering of stem cell and regenerative medicine researchers unites scientists, clinicians, and industry leaders from around the world to share the latest breakthroughs and insights in the field. Over four days of plenary sessions, concurrent scientific tracks, and networking opportunities, attendees will explore cutting‑edge advances from basic biology to translational and clinical applications.

Whether you’re presenting your work or connecting with peers, ISSCR 2026 is an essential event for anyone shaping the future of stem cell science and human health.

Kevin Braeckmans, co‑founder and scientific driving force behind our LumiPore® technology, has been appointed CEO of Trince. Kevin has played a central role in building our technological foundation and translating it into impactful solutions for customers and partners around the world.

In his new role, Kevin will focus on executing Trince’s long‑term strategy, leading the team, driving commercial growth, and strengthening partnerships with customers, investors, and industry stakeholders.

At the same time, Philip Mathuis, co‑founder and CEO since the company’s inception, will transition to the role of Executive Chairman of the Board of Directors. As Executive Chairman, Philip will focus on shaping Trince’s long‑term vision, guiding corporate strategy, leading board governance, and strengthening high‑level relationships with investors and strategic partners.

With Kevin driving operational leadership and Philip guiding long‑term strategic direction, Trince is strongly positioned for its next phase of innovation and global expansion.

We are excited about what lies ahead as we continue advancing our technology and bringing impactful solutions to our partners and customers.

Alliance for Regenerative Medicine

The annual congress is their flagship event—bringing together leading academic researchers, clinicians, and biotech industry experts to foster education, knowledge exchange, and collaborative innovation.

As Europe’s leading drug discovery and life sciences conference will have scientific tracks covering topics including robotics, cell and disease models, ‘omics, AI, oncology and neurodegenerative disease.

Additionally, it serves as a powerful tool for reprogramming somatic cells and engineering stem cells, whether through genome editing techniques like CRISPR/Cas9 or by modulating gene expression at the RNA level using RNA interference (RNAi).

An attractive solution is Trince’s LumiPore® transfection platform, which combines efficiency with gentleness. It combines laser exposure with photothermal nanoparticles to transiently permeabilize the cellular plasma membrane, allowing external cargo molecules to penetrate the cells.

Our CEO and co-founder Philip Mathuis will present the current and future insights and applications for photoporation.

If you’re attending, send us a note in the partnering system to set up a meeting and view our company presentation on Wednesday, Oct. 9th at 9.45 am.